Home » Stocks » AMRN

Amarin Corporation Plc (AMRN)

Stock Price: $6.55 USD 0.24 (3.80%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 2.55B
Revenue (ttm) 590.09M
Net Income (ttm) -15.86M
Shares Out 389.70M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE 40.98
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $6.55
Previous Close $6.31
Change ($) 0.24
Change (%) 3.80%
Day's Open 6.59
Day's Range 6.34 - 6.63
Day's Volume 6,171,100
52-Week Range 3.64 - 20.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapen...

The Motley Fool - 1 week ago

Investors holding shares in these two companies need to practice patience.

Other stocks mentioned: CCL
Seeking Alpha - 1 week ago

Amarin Corporation PLC (AMRN) CEO John Thero Presents at the 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

GlobeNewsWire - 2 weeks ago

Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019

The Motley Fool - 2 weeks ago

Down 77% in 2020, Amarin's stock should zoom higher once Vascepa obtains European approval.

GlobeNewsWire - 2 weeks ago

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer...

Zacks Investment Research - 3 weeks ago

Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

The Motley Fool - 3 weeks ago

These companies are eager to say good riddance to the year that was.

Other stocks mentioned: ICPT, IVR, NGL, NXTC, PBF, SNDL, TCDA, TELL, WPG
GuruFocus - 4 weeks ago

Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which...

Other stocks mentioned: BMRN
GlobeNewsWire - 1 month ago

REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers

GlobeNewsWire - 1 month ago

VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitiv...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT® EPA, Primary Results of the...

CNBC Television - 1 month ago

These are the stocks seeing the most insider buying this week

Brian Sullivan on the top companies this week whose executives are purchasing their own stock, on Worldwide Exchange.

Other stocks mentioned: BIIB, KDP, LMNX
Seeking Alpha - 1 month ago

Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)

GlobeNewsWire - 1 month ago

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates ...

GlobeNewsWire - 2 months ago

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer...

Seeking Alpha - 2 months ago

Amarin lost its generic appeal and the stock has faltered badly. People are possibly ignoring the vast European market and also what's left of the US market may be protected by manufacturing h...

Seeking Alpha - 2 months ago

Amarin's legal loss at the U.S. appeals court sent the stock lower. Positive clinical data from China partner a catalyst.

The Motley Fool - 2 months ago

After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.

InvestorPlace - 2 months ago

AMRN stock is climbing higher Thursday thanks to good news from a clinical trial in China. Here's what you should know about Amarin now.

GlobeNewsWire - 2 months ago

Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol ( LDL-C ) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per ...

Seeking Alpha - 2 months ago

Amarin Corporation PLC (AMRN) Presents at Jefferies Virtual London Healthcare Broker Conference Call - (Transcript)

GlobeNewsWire - 2 months ago

Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effective ness in reducing major adverse cardiovascular events (MACE) in studi...

Seeking Alpha - 2 months ago

Amarin Corporation plc (AMRN) Presents at Stifel Virtual Healthcare Conference (Transcript)

GlobeNewsWire - 2 months ago

VASCEPA®, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events ( MACE ) in post hoc exploratory analyses of patients with a histor...

GlobeNewsWire - 2 months ago

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer...

Zacks Investment Research - 2 months ago

Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.

Seeking Alpha - 2 months ago

Amarin Corporation plc (AMRN) CEO John Thero on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Total Revenue Increased 39 % in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds

The Motley Fool - 2 months ago

Here's why the stock prices of Tesla, Zoom, and Amarin are being driven by overexuberant speculation.

Other stocks mentioned: TSLA, ZM
The Motley Fool - 2 months ago

The heart drug continues to test well in clinical trials.

GlobeNewsWire - 2 months ago

Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT

GlobeNewsWire - 3 months ago

New analysis of contemporary real-world data presented at American Society of Nephrology (ASN) Kidney Week 2020 New analysis of contemporary real-world data presented at American Society of Ne...

GuruFocus - 3 months ago

The health care strategy analyst at Jefferies said he expects to see acquisitions in the pharma and biotech space in the $5 billion to $10 billion range, according to an article in FierceBiote...

Other stocks mentioned: ALXN, BMRN
GlobeNewsWire - 3 months ago

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior ...

Benzinga - 3 months ago

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15)

Other stocks mentioned: GLPG
GlobeNewsWire - 3 months ago

VASCEPA ® , c ompared with placebo, significantly reduced primary composite first and total MACE (m ajor a dverse c ardiovascular e vents ) in post hoc exploratory analyses of patients with a ...

The Motley Fool - 3 months ago

The stocks of Amarin and Clean Energy Fuels are down 90% off their highs -- but both could bounce back in a big way.

Other stocks mentioned: CLNE
Zacks Investment Research - 3 months ago

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

GlobeNewsWire - 3 months ago

Data presented provides additional insight into potential mechanisms by which VASCEPA lowers cardiovascular risk Data presented provides additional insight into potential mechanisms by which V...

Seeking Alpha - 4 months ago

Amarin Corporation plc (AMRN) CEO John Thero Presents at Cantor Virtual Global Healthcare Conference (Transcript)

GlobeNewsWire - 4 months ago

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive offi...

Seeking Alpha - 4 months ago

Amarin shares have taken a beating this week during the appellate hearing and especially after the adverse ruling came down on September 3.

Zacks Investment Research - 4 months ago

Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.

The Motley Fool - 4 months ago

Just one day after hearing arguments, the U.S. Court of Appeals delivered a ruling that Amarin shareholders did not want to hear.

GlobeNewsWire - 4 months ago

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals fo...

Seeking Alpha - 4 months ago

Amarin's Vascepa Data, And Other News: The Good, Bad And Ugly Of Biopharma

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - September 2, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inve...

InvestorPlace - 4 months ago

Peloton, Docusign, MongoDB, Amarin and SmileDirectClub were our top stock trades for Thursday. So, let's take a closer look at the charts.

Other stocks mentioned: PTON, SDC, DOCU, MDB

About AMRN

Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. T... [Read more...]

Industry
Biotechnology
IPO Date
Apr 1, 1993
CEO
John Thero
Employees
965
Stock Exchange
NASDAQ
Ticker Symbol
AMRN
Full Company Profile

Financial Performance

In 2019, Amarin's revenue was $429.76 million, an increase of 87.49% compared to the previous year's $229.21 million. Losses were -$22.65 million, -80.55% less than in 2018.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Amarin stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 52.67% from the latest price.

Price Target
$10.00
(52.67% upside)
Analyst Consensus: Buy